Novo Nordisk’s diabetes drug Ozempic has shown promise in reducing alcohol use in a new study. Researchers found that people taking Ozempic experienced significant reductions in drinking and heavy drinking days compared to those receiving a placebo.
The study, which involved 48 adults with alcohol-use disorder, lasted for over two months and used low doses of semaglutide, the active ingredient in Ozempic. Results showed that participants who took Ozempic drank 30% less on average on days they consumed alcohol, compared to an average reduction of 2% in the placebo group.
While the study’s findings are promising, larger and longer studies will be needed to confirm the effects of Ozempic on addictive behaviors. The results also suggest that Ozempic may reduce both alcohol and nicotine use.
The discovery of Ozempic’s potential in reducing alcohol use could have significant implications for those struggling with addiction. As demand for GLP-1 weight loss drugs has skyrocketed, some patients are turning to telehealth providers to access these medications. However, primary care physicians are concerned about the risks associated with third-party telehealth providers, including overprescribing and continuity of care.
The study’s findings have sparked interest in the pharmaceutical industry, with companies like CVS Health exploring ways to manage the costs of breakthrough gene therapies, such as sickle cell treatments. As the healthcare landscape continues to evolve, it will be important to monitor the progress of these new treatments and their potential impact on patients’ lives.
Source: https://www.cnbc.com/2025/02/19/healthy-returns-ozempic-helps-curb-alcohol-use-in-new-study.html